233 related articles for article (PubMed ID: 32048727)
1. IFN-γ/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy.
Grieco T; Porzia A; Paolino G; Chello C; Sernicola A; Faina V; Carnicelli G; Moliterni E; Mainiero F
Int J Dermatol; 2020 May; 59(5):590-594. PubMed ID: 32048727
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab response correlates with reduced IFN-γ-, IL-10- and IL-31-secreting cells in chronic spontaneous urticaria.
Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2078-2085. PubMed ID: 31954076
[TBL] [Abstract][Full Text] [Related]
5. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
8. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
11. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
12. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
[TBL] [Abstract][Full Text] [Related]
13. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU.
Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M
Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912
[No Abstract] [Full Text] [Related]
14. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria.
Sabag DA; Matanes L; Bejar J; Sheffer H; Barzilai A; Church MK; Toubi E; Maurer M; Vadasz Z
Clin Exp Allergy; 2020 Jul; 50(7):799-804. PubMed ID: 32412136
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy.
Liao SL; Yu M; Zhao ZT; Maurer M
Front Immunol; 2021; 12():652973. PubMed ID: 33796115
[TBL] [Abstract][Full Text] [Related]
19. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
20. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
